title: Outcome and clinical-biological characteristics of patients with advanced breast cancer undergoing removal of ovarian/pelvic metastases.
abstract: BACKGROUND
  Patients with metastatic breast cancer to the ovary, without tumor debulking and after systemic therapy, have a 5-year survival rate < 10%.
  
  
  METHODS
  We analyzed a series of 37 patients, operated in one institution over 10 years, for both the primary tumor (PT) and ovarian/pelvic metastases (OPM). Estrogen receptors (ER), progesterone receptors (PgR), HER-2 and Ki-67 were determined.
  
  
  RESULTS
  Patients were predominantly young: 27 (73%) patients were < 50 years. Average ER/PgR expression did not change significantly between PT (mean ER = 66%, PgR = 35%) and OPM (mean ER = 67%, PgR = 28%). Median time to OPM was 42 months (range 0-176); 5-year OS after OPM was 51% (95% confidence interval 32% to 67%). When combining ER and PgR status, patients with ER > 50% on both PT and OPM and with PgR > 50% on PT and/or OPM (good prognosis, 11 patients) had a better outcome versus0 patients with ER and PgR ≤ 50% on both PT and OPM (bad prognosis, eight patients) and also versus the remaining patients (intermediate prognosis, 18 patients), P value = 0.010.
  
  
  CONCLUSIONS
  Patients with OPM from breast cancer show a favorable prognosis after tumor debulking, whether it was radical or not, especially when a high expression of ER and PgR is present in both PT and OPM.
authors.affiliation: Department of Medicine, Division of Medical Oncology. Electronic address: elisabetta.munzone@ieo.it.
authors.forename: E
authors.initials: E
authors.lastname: Munzone
authors.affiliation: Division of Epidemiology and Biostatistics.
authors.forename: E
authors.initials: E
authors.lastname: Botteri
authors.affiliation: Department of Medicine, Division of Medical Oncology.
authors.forename: A
authors.initials: A
authors.lastname: Esposito
authors.affiliation: Department of Medicine, Division of Medical Oncology.
authors.forename: A
authors.initials: A
authors.lastname: Sciandivasci
authors.affiliation: Division of Gynecology.
authors.forename: D
authors.initials: D
authors.lastname: Franchi
authors.affiliation: Division of Pathology, Istituto Europeo di Oncologia, Milano, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Pruneri
authors.affiliation: Division of Epidemiology and Biostatistics.
authors.forename: N
authors.initials: N
authors.lastname: Rotmensz
authors.affiliation: Department of Medicine, Division of Medical Oncology.
authors.forename: G
authors.initials: G
authors.lastname: Curigliano
authors.affiliation: Department of Medicine, Division of Medical Oncology.
authors.forename: L
authors.initials: L
authors.lastname: Adamoli
authors.affiliation: Division of Gynecology.
authors.forename: L
authors.initials: L
authors.lastname: Bocciolone
authors.affiliation: Department of Medicine, Division of Medical Oncology.
authors.forename: A
authors.initials: A
authors.lastname: Goldhirsch
authors.affiliation: Department of Medicine, Division of Medical Oncology.
authors.forename: F
authors.initials: F
authors.lastname: Nolé
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor; D001943:Breast Neoplasms / Q000401:mortality* / Q000473:pathology / Q000601:surgery*; D005260:Female; D006801:Humans; D019394:Ki-67 Antigen / Q000378:metabolism; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000401:mortality / Q000556:secondary* / Q000601:surgery; D010386:Pelvic Neoplasms / Q000401:mortality / Q000556:secondary* / Q000601:surgery; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D019394:Ki-67 Antigen; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C508053:ERBB2 protein, human